Abstract:Pancreatic cancer, often termed the "silent killer" due to its vague symptoms and late diagnosis, continues to challenge oncologists with its significant treatment challenges and poor prognosis. Standard-of-care regimens, such as FOLFIRINOX (FFX) and Gemcitabine + nab-paclitaxel (GnP), show varied efficacy among patients. Understanding the factors that contribute to these varied responses is crucial for advancing personalized treatment strategies. This study uses NetraAI, a novel machine learning (ML) approach to analyze whole genome sequencing (WGS) and RNA sequencing (RNASeq) data from pancreatic ductal adenocarcinoma (PDAC) subjects (n=208) prior to FFX or GnP first-line combination therapy from the COMPASS trial, aiming to identify key variables that distinguish between responses to these two therapeutic regimens. NetraAI identifies explainable subpopulations within clinical trial data defined by a set of driving variables (i.e., hypotheses) related to drug response. This approach focuses on explaining only subjects that collectively represent a real effect and does not forcibly explain everyone, to avoid overfitting. Our analysis identified several key factors significantly correlating with treatment response. Downregulated LRRC8E and upregulated PTPRH showed favourable response to GnP, while upregulated UTG1A13p was associated with FFX response. Across all patients (stable disease, partial response, complete response) CLEC19A and LRRC29 expression were associated with better response to both FFX and GnP, suggesting that they may play a role in the chemotherapy response mechanisms. The NetraGPT module, leverages large language models (LLMs) and NetraAI insights to further query trial results. Querying NetraGPT, we identified a link between LRRC29 and HOOK1, associated with SHP, which has been linked to GnP response in non-small cell lung cancer. These findings suggest that chemotherapy response may be cancer-agnostic, depending on the chemotherapeutic agent, with LRRC29 expression discriminating selecting GnP versus FFX treatment. Our findings highlight the potential of AI in elucidating complex relationships within clinical trial data, offering valuable insights into the determinants of treatment response in pancreatic cancer to achieve more personalized cancer care. The identified biomarkers provide a promising foundation for developing personalized treatment strategies, enhancing the precision of therapeutic decisions. Integrating explainable ML methods for small and medium sized clinical data with LLMs provides an exciting step forward. Retrieval Augmentation allows researchers to create LLMs that are designed to answer questions about heterogeneous patient populations through the vantage of the various insights that have been discovered via specialized ML methods such as NetraAI and its NetraGPT module. We will provide a demo of how an interactive LLM was used to derive new insights into PDAC that may pave the way to precision treatment and explain how researchers can begin to create their own versions of these tools. Citation Format: Joseph Geraci, Bessi Qorri, Mike Tsay, Christian Cumbaa, Paul Leonchyk, Larry Alphs, Luca Pani. An AI approach to unraveling treatment response in pancreatic cancer: Insights from the COMPASS trial leveraging large language models (LLMs) [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research; 2024 Sep 15-18; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2024;84(17 Suppl_2) nr B066.

Using Retrieval-Augmented Generation to Capture Molecularly-Driven Treatment Relationships for Precision Oncology

Large language models for precision oncology: Clinical decision support through expert-guided learning.

Retrieval-Augmented Generation for Generative Artificial Intelligence in Medicine

Improved precision oncology question-answering using agentic LLM

PubMed Retrieval with RAG Techniques

Explainable Biomedical Hypothesis Generation via Retrieval Augmented Generation enabled Large Language Models

Retrieval-augmented large language models for clinical trial screening.

A RAG Chatbot for Precision Medicine of Multiple Myeloma

Leveraging Large Language Models for Decision Support in Personalized Oncology

Conditional Generative Adversarial Networks for Individualized Treatment Effect Estimation and Treatment Selection

Onco-Retriever: Generative Classifier for Retrieval of EHR Records in Oncology

Improving accuracy of GPT-3/4 results on biomedical data using a retrieval-augmented language model

Abstract 2315: AI-enabled precision oncology era: Advanced and interactive interpretation of next-gneneration sequencing (NGS) reports

Abstract 3509: Using generative AI for filtering and comprehension of drug target discovery screen results

How do you know that? Teaching Generative Language Models to Reference Answers to Biomedical Questions

Rationale-Guided Retrieval Augmented Generation for Medical Question Answering

Abstract B066: An AI approach to unraveling treatment response in pancreatic cancer: Insights from the COMPASS trial leveraging large language models (LLMs)

Abstract 3524: Leveraging ChatGPT for literature-based inference of drug-gene relationships in cancer

Development and Testing of Retrieval Augmented Generation in Large Language Models -- A Case Study Report

#1506 Uremic toxicity: gaining novel insights through AI-driven literature review

Leveraging State-of-the-Art AI Algorithms in Personalized Oncology: From Transcriptomics to Treatment